en · de · es · pt
lab-handbook.peptides5388.com › Topic › Background And Mechanism — Deep Dive

Background And Mechanism — Deep Dive

By Editorial Desk · published 2025-06-30 · last reviewed 2025-07-29 · Topic

This is a working overview of purity testing, written for readers who want more than a one-paragraph summary but less than a textbook.

This page was last updated on 2025-07-29 and is reviewed periodically as new material appears.

Background and Mechanism

At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.

Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.

Background and Research Status

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.

REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.

Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.

Sr9009 at a glance

PropertyValueNotes
Molecular formulaC20H24ClN3O4SDerived from published structure.
Molecular weight437.94 g/molCalculated value.
AppearanceWhite to off-white solidTypical for purified research samples.
SolubilityDMSO, ethanol; low in waterClass: poorly water-soluble.
Typical storage-20 °C, desiccated, protected from lightLimits degradation.

SR9009 Background and Receptor Mechanism

SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.

Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.

SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.

Related pages on this site

Handling, Analysis, and Regulation

Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.

Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.

Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.

Handling Storage and Quality Control

Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.

Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.

Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.

Supporting material

===== Czech Republic ===== As of May 2023, the State Agricultural and Food Inspection of the Czech Republic is putting together broad regulations regarding a ban on CBD products. They will make it illegal to sell products containing cannabidiol and other cannabinoids derived from hemp, as a result of EU Novel Food Regulation. In case of Czech Republic, European Industrial Hemp Association has submitted an official request to the Czech Republic to recognize natural hemp extracts with cannabinoids as traditional food.

=== Cuban opposition === On 6 February, El País conducted interviews with various Cuban dissidents, including José Daniel Ferrer, Manuel Cuesta Morúa, and María Payá Acevedo. Their reactions were a mix of hope and warning against manipulations, including views that the Cuban government could cease talks when it stabilizes itself. On 22 May, Cuban opposition leader Ferrer claimed that there is no doubt that the communist regime will end by the end of 2026.

== History == The use of cold for pain relief and as an anti-inflammatory has been known since the time of Hippocrates (460–377 BC). Since then there have been numerous accounts of ice used for pain relief, including from the Ancient Egyptians and Avicenna of Persia (982–1070 AD). In 1812, Napoleon's surgeon general noted that half-frozen soldiers from the Moscow battle were able to tolerate amputations with reduced pain. In 1851, ice and salt mixtures were promoted by Arnott for the treatment of nerve pain. Campbell White, in 1899, was the first to use refrigerants medically, and Allington, in 1950, was the first to use liquid nitrogen for medical treatments. In 1961, Cooper et al. created an early cryoprobe that reached −190 °C using liquid nitrogen. Shortly thereafter, in 1967, an ophthalmic surgeon named Amoils used carbon dioxide and nitrous oxide to create a cryoprobe that reached −70 °C.

Sources: en.wikipedia.org

Notes from published material

== Education == Kowalska received a master's degree in chemistry in 1968 and a PhD in physical chemistry in 1972, both from Higher Pedagogical School in Katowice, which became University of Silesia in Katowice. She conducted post-doctoral research at University of Salford in the UK, under the supervision of Hans Suschitzky. She received a habilitation degree in 1988 from Maria Curie-Skłodowska University, with the habilitation dissertation titled A New Thermodynamic Model of the Chromatographic Process and its Applications.

In all, over a million Canadians served in the armed forces during the Second World War. Canadian troops played important roles in many key battles of the war, including the failed 1942 Dieppe Raid, the Allied invasion of Italy, the Normandy landings, the Battle of Normandy, and the Battle of the Scheldt in 1944. Canada provided asylum for the Dutch monarchy while that country was occupied and is credited by the Netherlands for major contributions to its liberation from Nazi Germany.

== Efforts against proliferation == Antiproliferation or anti-proliferation: inhibiting cell multiplication; also efforts to slow, stop, or prevent the spread of weapons (nuclear, chemical, biological weapons, missiles) and technology, small arms, illicit drugs Counterproliferation or counter-proliferation: efforts to slow, stop, or prevent the spread of weapons (nuclear, chemical, biological weapons, missiles) and technology, small arms, illicit drugs

1 of the 20 Greatest WWE Wrestlers Of All Time Texas Wrestling Alliance TWA Tag Team Championship (1 time) – with Rod Price World Championship Wrestling WCW World Television Championship (2 times) WCW United States Heavyweight Championship (2 times) WCW World Tag Team Championship (1 time) – with Brian Pillman NWA World Tag Team Championship (1 time) – with Brian Pillman World Wrestling Federation/World Wrestling Entertainment/WWE WWF Championship (6 times) WWF Intercontinental Championship (2 times) WWF Tag Team Championship (4 times) – with Shawn Michaels (1), Dude Love (1), The Undertaker (1), and Triple H (1) Million Dollar Championship (1 time) King of the Ring (1996) Royal Rumble (1997, 1998, 2001) Undisputed WWF Championship #1 Contenders Tournament (2002) Fifth Triple Crown Champion Slammy Award (2 times) Freedom of Speech (1997) Best Original WWE Network Show – Stone Cold Podcast (2015) WWE Hall of Fame (2 times) Class of 2009 – individually Class of 2025 – Immortal Moment vs. Bret Hart at WrestleMania 13 Wrestling Observer Newsletter Best Box Office Draw (1998, 1999) Best Brawler (2001) Best Gimmick (1997, 1998) Best Heel (1996) Best on Interviews (1996–1998, 2001) Best Non-Wrestler (2003) Feud of the Year (1997) vs. The Hart Foundation Feud of the Year (1998, 1999) vs. Vince McMahon Match of the Year (1997) vs. Bret Hart in a submission match at WrestleMania 13 Most Charismatic (1997, 1998) Rookie of the Year (1990) Tag Team of the Year (1993) with Brian Pillman as The Hollywood Blonds Worst Worked Match of the Year (1991) with Terrance Taylor vs.

Sources: en.wikipedia.org

Background from the literature

The carbohydrate-insulin model (CIM) posits that obesity is caused by excess consumption of carbohydrate, which then disrupts normal insulin metabolism leading to weight gain and weight-related illnesses. It is contrasted with the mainstream energy balance model (EBM), which holds that obesity is caused by an excess in calorie consumption compared to calorie expenditure. According to the carbohydrate–insulin model, low-carbohydrate diets would be the most effective in causing long-term weight loss. Notable proponents of the carbohydrate–insulin model include Gary Taubes and David Ludwig. The CIM has been tested in mice and humans. Although some experts consider that these studies falsified the CIM, proponents disagree. Available evidence does not support the existence of a long-term advantage in weight loss for low-carbohydrate diets.

The probiotic The effect of Lactobacillus reuteri is attributed to immunomodulating substances that inhibit the production of the cytokine TNF (tumor necrosis factor) in humans. Examination of the membrane lipids of various strains of Lactobacillus reuteri shows that only the TNF-inhibiting strains have lactobacillic acid. In this experiment, the cfa gene was also inactivated in a lactobacillic acid-producing bacterial strain and the mutants were cultivated. The supernatant was tested in a cell culture and - in contrast to the supernatant of the wild type - suppresses the production of TNF. However, the addition of lactobacillic acid as a pure substance does not lead to the inhibition of cytokine production. Thus, the fatty acid is only indirectly involved in the immunomodulatory activity of L. reuteri; an altered membrane fluidity is cited as a possible explanation.

America's Taco Shop – a restaurant chain with locations only in Arizona. Baja Fresh – a chain of fast-casual Tex Mex restaurants in the United States, Portugal and Kuwait. Blimpie – an American submarine sandwich chain with locations in the United States and Kuwait Cereality – a chain with stores in Texas, West Virginia, Minnesota and Ohio; also formerly had stores in Illinois. Cold Stone Creamery – an ice cream parlor restaurant chain with stores in Bahrain, Canada (partnership with Burger King/Tim Hortons from 2008 to 2014 now terminated), China, Denmark, Egypt, India, Indonesia, Japan, Kuwait, Mexico, Nigeria, Oman, Qatar, South Korea, Taiwan, United Arab Emirates, United States, Philippines, Kenya, Bangladesh, Pakistan, Finland, Jordan, Norway, Saudi Arabia, Sweden, Vietnam, Singapore and Lebanon Frullati Cafe & Bakery – chain with stores in Kuwait and the United States. Grabbagreen – a chain of restaurants offering healthy foods and smoothies. Great Steak – a restaurant chain with locations in Canada, Mexico, Kuwait and the United States. Founded 1982; formerly "Great Steak & Potato Company". In 2000, it had 225 locations. Sold to Kahala Brands in 2004; expansion planned into South Korea. Johnnie's New York Pizzeria – restaurant chain with stores in California, Florida, Oregon, and Texas. Kahala Coffee Traders (California, Utah) La Salsa – a chain of fast-casual Tex Mex restaurants in the United States Maui Wowi Hawaiian – chain with stores in the United States, Mexico, Saudi Arabia and the United Arab Emirates.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.

Is SR9009 a SARM?

No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.

Are there human trials of SR9009?

Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.

What is SR9009?

It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.

Network